CD11c as a novel target to improve neutrophil effector functions and sepsis outcome
CD11c 作为改善中性粒细胞效应功能和脓毒症结局的新靶点
基本信息
- 批准号:10552923
- 负责人:
- 金额:$ 38.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAdultAdvocateAgingAgonistBindingBiological AssayBiological MarkersBloodBone MarrowCD34 geneCRISPR/Cas technologyCell Adhesion MoleculesCell surfaceCellsChildCirculationClinical TrialsComplement ReceptorDataDendritic CellsDevelopmentEmergency SituationEscherichia coliFutureGenerationsGenesGenetic TranscriptionGoalsGranulocyte Colony-Stimulating FactorGranulopoiesisHL-60 CellsHematopoietic stem cellsHeterogeneityHospital MortalityHospitalizationHost DefenseHumanITGAX geneITGB2 geneImmuneIn VitroIncidenceInfectionIntegrin BindingIntegrinsInterventionKnock-in MouseKnockout MiceLeukocytesLigand BindingLigandsMicrobeModelingMorbidity - disease rateMusOntologyOperative Surgical ProceduresOutcomeOutputPatientsPhagocytesPlayPopulationProductionProliferatingReportingResearchRoleSamplingSepsisSignal PathwaySterilitySupportive careSystemic Inflammatory Response SyndromeTestingTherapeuticTherapeutic InterventionTimeTranslationsUnited StatesWild Type Mouseagedantagonistantimicrobialcandidate identificationcecal ligation puncturecostcytokineexperimental studyimprovedimproved outcomein vivomembermicrobialmortalitymouse modelneutrophilnovelnovel therapeuticsperipheral bloodpolymicrobial sepsisprecursor cellsepticseptic patientssingle-cell RNA sequencingsmall moleculetranscriptomic profiling
项目摘要
Project Summary/ Abstract
Sepsis remains to be associated with a high mortality of 20 to 30% with annual cost of $24 billion, accounting
for nearly one-fifth of the total aggregate costs in all the hospitalizations in the United States. Current sepsis
management is supportive. Therefore, identifying therapeutic approaches is an urgent task to improve the
outcome of sepsis. Neutrophils eradicate microbes as the first-line defense innate immune cells. In sepsis,
exaggerated de novo neutrophil production called emergency granulopoiesis occurs mainly via G-CSF
production. However, immature neutrophils are also released into a circulation to meet a high demand for
neutrophil number, but they have less antimicrobial defense functions, leading to worse host defense in septic
patients. G-CSF itself does not trigger full neutrophil maturation. Thus, an intervention to attain the
enhancement of neutrophil maturation is critical in sepsis for better host defense. Integrin CD11c was
considered a sensitive marker to differentiate sepsis from systemic inflammatory response syndrome. We
previously showed that CD11c KO mice had worse survival in the polymicrobial sepsis induced by cecal
ligation and puncture (CLP) surgery, indicating the critical role of CD11c in sepsis. There has been a paucity of
research about its functional role in vivo. We unexpectedly identified that CD11c was expressed in the bone
marrow (BM) neutrophils (largely intracellular) and its deficiency was associated with less BM neutrophil
maturation. In a mouse model to recapitulate emergency granulopoiesis, mature neutrophils were released in
significantly less quantity in CD11c KO mice compared to wild type (WT) mice, further suggesting its
importance in neutrophil maturation. We created CD11c constitutively active knock-in (KI) mice, which
demonstrated to have more mature neutrophils in the BM in a steady-state condition and during infection with
better bacterial eradication and outcomes. In addition, our in vitro neutrophil maturation experiments using
primary murine CD11c KO neutrophils or HL-60 cells devoid of CD11c by CRISPR/Cas9 technology showed
less neutrophil maturation. Based on these results, we hypothesized that CD11c activity would significantly
regulate the degree of neutrophil maturation in a steady state and emergency granulopoiesis in a cell-intrinsic
manner. Our preliminary data suggested that CD11c would also regulate a subset of neutrophil effector
functions irrelevant of maturation. Thus, we will determine the role of CD11c in neutrophil maturation and
effector functions in a steady state and sepsis in Aim 1 and Aim 2. Because IQGAP1 was suggested to be a
binding partner for CD11c, its role will also be studied to delineate the mechanism of how CD11c regulates
neutrophil maturation and effector functions. Studies will be done by using human sepsis subjects and murine
models. Because there are no CD11c small molecule agonists and antagonists available, we will screen them
in Aim 3. Upon the completion of the proposal, we expect that we would solidify that CD11c would be a critical
regulator of neutrophil maturation and effector functions for a therapeutic intervention in sepsis.
项目摘要/摘要
脓毒症仍然与20%到30%的高死亡率有关,每年的成本为240亿美元。
占美国所有住院总费用的近五分之一。流行性脓毒症
管理层表示支持。因此,确定治疗方法是一项紧迫的任务,以改善
败血症的结局。中性粒细胞作为先天免疫细胞的第一道防线消灭微生物。在脓毒症中,
夸大的从头产生的中性粒细胞称为紧急粒细胞生成,主要通过G-CSF发生
制作。然而,未成熟的中性粒细胞也被释放到循环中,以满足对
中性粒细胞数量较多,但其抗菌防御功能较差,导致脓毒症患者宿主防御能力较差
病人。G-CSF本身不会触发中性粒细胞的完全成熟。因此,通过干预来实现
促进中性粒细胞成熟是脓毒症中更好的宿主防御的关键。整合素CD11c为
被认为是区分脓毒症和全身炎症反应综合征的敏感标记物。我们
以往研究表明,CD11c KO小鼠在盲肠诱导的多菌败血症中存活率较低
结扎和穿孔(CLP)手术,表明CD11c在脓毒症中的关键作用。已经有很少的
研究其在体内的功能作用。我们意外地发现CD11c在骨骼中表达
骨髓(BM)中性粒细胞(主要在细胞内)及其缺陷与BM中性粒细胞减少有关
成熟。在总结紧急粒细胞生成的小鼠模型中,成熟的中性粒细胞在
CD11c KO小鼠与野生型(WT)小鼠相比数量显著减少,进一步表明其
中性粒细胞成熟的重要性。我们创造了CD11c结构性活性敲入(KI)小鼠,它
在稳定状态和感染期间,骨髓中有更多成熟的中性粒细胞
更好的细菌根除和结果。此外,我们的体外中性粒细胞成熟实验使用
CRISPR/Cas9技术显示原代小鼠CD11c KO中性粒细胞或HL-60细胞缺乏CD11c
中性粒细胞成熟较少。基于这些结果,我们假设CD11c的活性将显著
调节中性粒细胞在稳定状态下的成熟程度和细胞内的紧急粒细胞生成
举止。我们的初步数据表明,CD11c也将调节中性粒细胞效应的一个子集。
与成熟无关的功能。因此,我们将确定CD11c在中性粒细胞成熟和
效应器功能稳定,目标1和目标2败血症。因为IQGAP1被认为是一个
作为CD11c的结合伙伴,其作用也将被研究,以阐明CD11c如何调节的机制
中性粒细胞成熟和效应功能。研究将通过使用人类脓毒症受试者和小鼠进行
模特们。由于目前尚无CD11c小分子激动剂和拮抗剂,我们将对其进行筛选。
在目标3.在提案完成后,我们预计我们将巩固CD11c将是一个关键
中性粒细胞成熟调节因子和效应器功能用于脓毒症的治疗干预。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Koichi Yuki其他文献
Koichi Yuki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Koichi Yuki', 18)}}的其他基金
The role of damage-associated molecular patterns in perioperative morbidities and mortalities of pediatric congenital heart diseases
损伤相关分子模式在小儿先天性心脏病围手术期发病率和死亡率中的作用
- 批准号:
10669290 - 财政年份:2022
- 资助金额:
$ 38.94万 - 项目类别:
The role of damage-associated molecular patterns in perioperative morbidities and mortalities of pediatric congenital heart diseases
损伤相关分子模式在小儿先天性心脏病围手术期发病率和死亡率中的作用
- 批准号:
10492851 - 财政年份:2022
- 资助金额:
$ 38.94万 - 项目类别:
Optimization of anesthetic/sedative regimen for pulmonary pathophysiology in cystic fibrosis patients
囊性纤维化患者肺部病理生理学麻醉/镇静方案的优化
- 批准号:
10181647 - 财政年份:2021
- 资助金额:
$ 38.94万 - 项目类别:
Optimization of anesthetic/sedative regimen for pulmonary pathophysiology in cystic fibrosis patients
囊性纤维化患者肺部病理生理学麻醉/镇静方案的优化
- 批准号:
10341229 - 财政年份:2021
- 资助金额:
$ 38.94万 - 项目类别:
Surgical site infections and the role of anesthesia and bacterial ion transporters
手术部位感染以及麻醉和细菌离子转运蛋白的作用
- 批准号:
10402288 - 财政年份:2020
- 资助金额:
$ 38.94万 - 项目类别:
Surgical site infections and the role of anesthesia and bacterial ion transporters
手术部位感染以及麻醉和细菌离子转运蛋白的作用
- 批准号:
9883315 - 财政年份:2020
- 资助金额:
$ 38.94万 - 项目类别:
The impact of anesthetic selection on sepsis outcome and its mechanism
麻醉选择对脓毒症结局的影响及其机制
- 批准号:
9250801 - 财政年份:2016
- 资助金额:
$ 38.94万 - 项目类别:
The impact of anesthetic selection on sepsis outcome and its mechanism
麻醉选择对脓毒症结局的影响及其机制
- 批准号:
9452998 - 财政年份:2016
- 资助金额:
$ 38.94万 - 项目类别:
The impact of anesthetic selection on sepsis outcome and its mechanism
麻醉选择对脓毒症结局的影响及其机制
- 批准号:
9072087 - 财政年份:2016
- 资助金额:
$ 38.94万 - 项目类别:
Immunomodulatory mechanism of volatile anesthetics
挥发性麻醉药的免疫调节机制
- 批准号:
8449579 - 财政年份:2012
- 资助金额:
$ 38.94万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 38.94万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 38.94万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 38.94万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 38.94万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 38.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 38.94万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 38.94万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 38.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 38.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 38.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)